

(2) A marked up version of the substitute specification showing all the changes (including the matter being added to and the matter being deleted from) to the specification of record. Numbering the paragraphs of the specification of record is not considered a change that must be shown pursuant to this paragraph.

(c) A substitute specification submitted under this section must be submitted in clean form without markings as to amended material. The paragraphs of any substitute specification, other than the claims, should be individually numbered in Arabic numerals so that any amendment to the specification may be made by replacement paragraph in accordance with § 1.121(b)(1).

(d) A substitute specification under this section is not permitted in a reissue application or in a reexamination proceeding.

No new matter has been added to the specification, as only amendments to the specification have been made in response to informalities highlighted by the Examiner. A marked-up version of the specification complying with 37 C.F.R. § 1.125(b)(2) is also filed herewith including individually numbered paragraphs complying with 37 C.F.R. § 1.125(b)(3).

IN THE CLAIMS

Please amend claims 1-8 as follows:

1. A peptide factor [derived from] comprising amino acid residues 33 to 42 of murine epidermal growth factor peptide [or a synthetic equivalent thereof] wherein:
 - a) the peptide factor is modified [to protect it from proteolytic degradation] such that at least one murine epidermal growth factor tyrosine amino acid residue is substituted with a tyrosine analogue or at least one murine epidermal growth factor arginine amino acid residue is substituted with an arginine analogue; and
 - b) the peptide factor binds to laminin receptors [wherein the modifications consist of at least one modification chosen from the group comprising; substitution of tyrosine by tyrosine analogues and substitution of arginine by arginine analogues].